Oaktree Specialty Lending Corporation (OCSL)
NASDAQ: OCSL · Real-Time Price · USD
15.62
-0.06 (-0.38%)
Nov 21, 2024, 10:59 AM EST - Market open

Company Description

Oaktree Specialty Lending Corporation is a business development company.

The fund specializing in investments in middle market, bridge financing, first and second lien debt financing, unsecured and mezzanine loan, mezzanine debt, senior and junior secured debt, expansions, sponsor-led acquisitions, preferred equity, and management buyouts in small and mid-sized companies.

It seeks to invest in education services, business services, retail and consumer, healthcare, manufacturing, food and restaurants, construction and engineering.

The firm also seeks investment in media, advertising sectors, software, IT services, pharmaceuticals, biotechnology, real estate management and development, chemicals, machinery, and internet and direct marketing retail sectors.

It invests between $5 million to $75 million principally in the form of one-stop, first lien, and second lien debt investments, which may include an equity co-investment component in companies.

The firm invest in companies having enterprise value between $20 million and $150 million and EBITDA between $3 million and $50 million.

The fund has a hold size of up to $75 million and may underwrite transactions up to $100 million. It primarily invests in North America.

The fund seeks to be a lead investor in its portfolio companies.

Oaktree Specialty Lending Corporation
Oaktree Specialty Lending logo
Country United States
Founded 2007
IPO Date Jun 12, 2008
Industry Asset Management
Sector Financials
CEO Armen Panossian

Contact Details

Address:
333 South Grand Avenue, 28th Floor
Los Angeles, California 90071
United States
Phone 213 830 6300
Website oaktreespecialtylending.com

Stock Details

Ticker Symbol OCSL
Exchange NASDAQ
Fiscal Year October - September
Reporting Currency USD
CIK Code 0001414932
CUSIP Number 67401P108
ISIN Number US67401P4054
Employer ID 26-1219283

Key Executives

Name Position
Armen Panossian J.D. Chief Executive Officer and Chief Investment Officer
Mathew M. Pendo President
Dr. Aman Kumar M.D. Managing Director and Co-Portfolio Manager of Life Sciences Direct Lending
Raghav Khanna Managing Director and Co-Portfolio Manager
Christopher McKown MD,Chief Financial Officer and Treasurer
Michael Mosticchio Investor Relations
Ashley Pak Chief Compliance Officer
Sandeep Kumar Khorana Managing Director of Origination
Lucia S. Kim Senior Vice President
Eric Johnson Managing Director

Latest SEC Filings

Date Type Title
Nov 19, 2024 8-K Current Report
Nov 19, 2024 10-K Annual Report
Oct 28, 2024 40-17G Filing
Aug 2, 2024 424B5 Filing
Aug 2, 2024 8-K Current Report
Aug 1, 2024 8-K Current Report
Aug 1, 2024 10-Q Quarterly Report
Jun 21, 2024 8-K Current Report
May 22, 2024 8-K Current Report
May 17, 2024 40-APP/A Filing